New Report Calls on Performance Payments for Pharma Companies

A new report suggests that pharmaceutical companies should be paid by the NHS depending on how effectively their products ultimately treat patients. This approach is advocated by the Social Market Foundation, with the organisation asserting that drugs which satisfy a particular criteria should be made eligible to pass through a new purchasing scheme. The Social Market Foundation believes that this would make medicines available for patients more rapidly. Based on this new suggestion, the NHS would... Readmore

New £3.4 Million Radiology Training Department Announced in Wales

A major academy intended to train radiologists and imaging professionals has been announced in Wales. £3.4 million of funding has been invested in the project by the Welsh government And the new National Imaging Academy for Wales will be based in Pencoed, Bridgend. It is hoped that it will be fully operational by the mid-point of 2018. Health Secretary Vaughan Gething announced the plan, indicating that the academy will "play an important role" in the training of radiologists, increasing... Readmore

Alexion Pharma and the National Institute for Health and Care Excellence Enter into New Agreement

Alexion Pharma and the National Institute for Health and Care Excellence have come to a new arrangement that widens NHS access to Strensiq for people with paediatric-onset hypophosphatasia. This will be extremely welcome considering the difficulty in treating this extremely rare genetic condition. Less than ten babies inherit this condition on an annual basis in England, but hypophosphatasia can be hugely debilitating for the few poor infants that suffer with it. Hypophosphatasia is characterised... Readmore

Oxford BioMedica Seals Major Novartis Deal

Oxford BioMedica has signed and sealed a major deal with Novartis, that will see a major collaboration between the two pharmaceutical giants. The agreement involves the Swiss pharmaceutical conglomerates being supplied with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products. This agreement is indicative of the strong relationship between the two companies, as the two had already penned a previous collaborative... Readmore

Infertile Women Denied Drug due to Cost Concerns

New research indicates that thousands of British women are being denied access to a drug which could cost as little as £4. And previous studies suggest that the medicine in question could increase chances of pregnancy by around 300%. Yet the NHS rationing body has rejected usage of the treatment, which is combined with insemination, for those women that have unexplained infertility. Guidance from the National Institute for Health and Care Excellence instead indicates that couples finding... Readmore

New Rheumatoid Arthritis Treatment Option to be Made Available on the NHS

A new treatment for rheumatoid arthritis could be made available on the NHS in the foreseeable future. Regulators ruled Eli Lilly’s Olumiant to be cost-effective meaning that some patients could benefit from the treatment in the coming months. Draft guidelines by the National Institute for Health and Care Excellence recommend Olumiant (baricitinib) as an option for treating severe active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with conventional... Readmore

Artificial Heart Pump Nearing UK Usage

Scientists in Wales have revealed that the first ever artificial heart pump in Britain is nearing real world functionality. Swansea University's Institute of Life Science indicates that the pump will be ready for usage on patients in the foreseeable future. Clinical trials are due to begin in late 2018 with the aim of a full rollout before the end of 2020. The pump can be implanted into a heart experiencing difficulties, with researchers stating that a decade of usage will be possible for each... Readmore

Association of the British Pharmaceutical Industry Suspends Astellas for Further 12 Months

Astellas UK’s membership of the Association of the British Pharmaceutical Industry has been suspended for 12 months. This is an extension of the existing exclusion for the pharmaceutical company, with serious breaches of the code of practice having led to this lengthy extension. The British pharmaceutical industry indicates that having assessed recent cases related to the company that there has been a “wholly inadequate oversight and control at both Astellas UK and Astellas Pharma Europe... Readmore

Breast Cancer Drugs Approved for NHS Usage

A new drug with the potential to extend the lives of women suffering from advanced breast cancer has been approved for routine NHS utilisation. Kadcyla had been rejected by the National Institute for Health and Care Excellence due to its expense back in 2016. This had provoked a strong negative reaction from campaigners at the time. But NHS England has now come to an agreement with the manufacture of the drug, Roche, which will make it available to around 1,200 women on an annual basis in England. The... Readmore

Antibiotic Spending Shows Massive Regional Variations

Analysis of spending across numerous clinical commissioning group areas reveals that the amount of money spent on antibiotics demonstrates significant regional variation. Indeed, the monies proffered on antibiotics varied 2.4-fold per weighted patient across the country in the first quarter of 2017, based on official data. Results acquired from NHS England information indicate that in the West London Clinical Commissioning Group approximately 47p was spent on average per weighted patient on antibacterial... Readmore

Opdivo U-Turn Promises Drug Access to British Patients

European Union regulators have cleared a spinal muscular atrophy therapy, with the hope that the new treatment can have a major impact on treating the condition. spinal muscular atrophy is a rare and often fatal genetic disease that impacts upon the muscular strength and movements. In response to this debilitating condition, the European commission has approved Biogen's Spinraza (nusinersen) as a first line treatment of 5q spinal muscular atrophy. This form of the disease accounts for approximately... Readmore

Rilpivirine HIV Drug Filed with US and European Regulators

ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU. The applications were submitted for a single-tablet, including two-drug regimen of dolutegravir and rilpivirine for maintenance treatment of HIV-1 infection. If approved, the therapy will be the first two-drug regimen for the maintenance treatment of HIV-1 infection offering patients who are virally suppressed the option to switch to a regimen which... Readmore
This site uses cookies. Find out more about this site’s cookies.